Use of inhibitors of the renin-angiotensin system
It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
1 . A method for the treatment or prevention of stroke or its recurrence, wherein said method comprises administering, to a patient in need of such treatment or prevention, an inhibitor of the rennin-angiotensin system.
2 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is an inhibitor of angiotensin-converting enzyme (“ACE”).
3 . The method as claimed in claim 2 , wherein the ACE inhibitor is selected from the group consisting of quinapril, captropril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, delapril, moveltipril and trandolapril.
4 . The method as claimed in claim 2 , wherein the ACE inhibitor is selected from the group consisting of quinapril, captopril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipri, cilazapril and lisinopril.
5 . The method as claimed in claim 2 , wherein the ACE inhibitor is ramipril.
6 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is an angiotensin receptor antagonist.
7 . The method as claimed in claim 6 , wherein the angiotensin receptor antagonist is an AT 1 receptor antagonist.
8 . The method as claimed in claim 7 , wherein the AT 1 receptor antagonist is selected from losartan, valsartan, irbesartan, candesartan, eprosartan, tasosartan and telmisartan.
9 . The method as calimed in claim 7 , wherein the AT 1 receptor antagonist is selected from the group consisting of losartan, valsartan, and irbesartan.
10 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is a neutral endopeptidase-inhibitor.
11 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is a rennin-inhibitor.
12 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is an inhibitor of kinin degradation.
13 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is a kininase-inhibitor.
14 . The method as claimed in claim 1 , wherein the inhibitor of the rennin-angiotensin system is lipophilic.